JP2003530872A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530872A5
JP2003530872A5 JP2001578467A JP2001578467A JP2003530872A5 JP 2003530872 A5 JP2003530872 A5 JP 2003530872A5 JP 2001578467 A JP2001578467 A JP 2001578467A JP 2001578467 A JP2001578467 A JP 2001578467A JP 2003530872 A5 JP2003530872 A5 JP 2003530872A5
Authority
JP
Japan
Prior art keywords
polypeptide
polynucleotide
symbol
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001578467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530872A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/013828 external-priority patent/WO2001081380A2/en
Publication of JP2003530872A publication Critical patent/JP2003530872A/ja
Publication of JP2003530872A5 publication Critical patent/JP2003530872A5/ja
Pending legal-status Critical Current

Links

JP2001578467A 2000-04-27 2001-04-27 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物 Pending JP2003530872A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20007400P 2000-04-27 2000-04-27
US60/200,074 2000-04-27
PCT/US2001/013828 WO2001081380A2 (en) 2000-04-27 2001-04-27 Immunogenic pneumococcal protein and vaccine compositions thereof

Publications (2)

Publication Number Publication Date
JP2003530872A JP2003530872A (ja) 2003-10-21
JP2003530872A5 true JP2003530872A5 (enExample) 2008-07-03

Family

ID=22740214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001578467A Pending JP2003530872A (ja) 2000-04-27 2001-04-27 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物

Country Status (6)

Country Link
US (1) US6689369B2 (enExample)
EP (1) EP1278856A2 (enExample)
JP (1) JP2003530872A (enExample)
AU (2) AU5577201A (enExample)
CA (1) CA2407455A1 (enExample)
WO (1) WO2001081380A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
EP1067962B1 (en) * 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
US6858706B2 (en) * 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
PL3752182T3 (pl) 2018-02-12 2024-11-25 Inimmune Corporation Ligandy receptorów toll-podobnych
CA3198876A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514308A (ja) * 1996-08-16 2000-10-31 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
CA2271720A1 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences

Similar Documents

Publication Publication Date Title
JP7641512B2 (ja) Tlr7アゴニストにカップリングする新規コロナウイルスポリペプチドワクチンおよびその適用
AU2007271350B2 (en) Small Streptococcus pyogenes antigens and their use
JP2002542827A5 (enExample)
CA2371714A1 (en) Streptococcus pneumoniae proteins and vaccines
CN103068838B (zh) 基于重组蛋白的抗链球菌感染疫苗
RU2757426C2 (ru) Иммунногенный слитый белок
JP2002507396A5 (enExample)
RU2008150400A (ru) Новая детерминанта вирулентности в пределах структурного гликопротеина е2 вируса классической лихорадки свиней
JP2003501110A5 (enExample)
CN113801207B (zh) 新型冠状病毒的串联表位多肽疫苗及其应用
JP2011506433A5 (enExample)
JP5437813B2 (ja) S.アガラクティエの防御タンパク質、その組み合わせ、およびそれを使用する方法
JP2002512800A5 (enExample)
JP2001516583A5 (enExample)
KR102675880B1 (ko) SARS-CoV-2 스파이크 단백질 및 면역글로불린의 Fc 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
CN118873646A (zh) 一种抑制a组链球菌感染的重组蛋白疫苗及其应用
KR102675879B1 (ko) SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
KR102675881B1 (ko) Pedv 스파이크 단백질 s1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
JP2024512722A (ja) 免疫原性融合タンパク質
CN107974458A (zh) 表达猪丹毒杆菌重组蛋白GAPDH的基因gapdh及其重组大肠杆菌与应用
CN114437235A (zh) 马链球菌马亚种8种蛋白的重组融合蛋白及其制备方法和应用
US7041295B2 (en) Compounds for treatment of infectious and immune system disorders and methods for their use
JP2004502782A5 (enExample)
WO2023044327A1 (en) Recombinant vaccine compositions
Yu et al. A DNA vaccine encoding the FMDV capsid precursor polypeptide P1 and the enhancing effect of bovine herpesvirus 1 VP22 protein as molecular adjuvant